Beyondspring Inc(BYSI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BYSI Beyondspring Inc

Pre-Mkt 01-22 06:00:03 EST

1.67

-0.03

-1.76%

High1.72	Low1.64	Vol25.89K
Open1.66	D1 Closing1.70	Amplitude4.71%
Mkt Cap68.67M	Tradable Cap50.47M	Total Shares41.12M
T/O43.82K	T/O Rate0.09%	Tradable Shares30.22M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BYSI","market":"US","secType":"STK","nameCN":"Beyondspring Inc","latestPrice":1.67,"timestamp":1769029200000,"preClose":1.7,"halted":0,"volume":25893,"delay":0,"changeRate":-0.01764705882352943,"floatShares":30219373,"shares":41122299,"eps":-0.014832,"marketStatus":"Pre-Mkt","change":-0.03,"latestTime":"01-22 06:00:03 EST","open":1.66,"high":1.72,"low":1.64,"amount":43824.384109800005,"amplitude":0.047059,"askPrice":2.05,"askSize":100,"bidPrice":1.6,"bidSize":48,"shortable":3,"etf":0,"ttmEps":-0.014832,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1769092200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1489035600000,"exchange":"NASDAQ","adjPreClose":1.67,"postHourTrading":{"tag":"盘后","latestPrice":1.67,"preClose":1.67,"latestTime":"16:21 EST","volume":14,"amount":23.16,"timestamp":1769030470328,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6596640155762702,"impliedVol":0.4474,"impliedVolPercentile":0.628},"requestUrl":"/m/hq/s/BYSI/wiki","defaultTab":"wiki","newsList":[{"id":"2591624439","title":"BeyondSpring Sells $35.4 Million Stake in SEED Therapeutics to Strategic Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2591624439","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591624439?lang=en_us&edition=fundamental","pubTime":"2025-12-16 05:30","pubTimestamp":1765834258,"startTime":"0","endTime":"0","summary":"BeyondSpring Inc. has entered into a series of Preferred Share Purchase Agreements to sell a total of 8,333,637 Series A-1 Preferred Shares of SEED Therapeutics Inc. for an aggregate purchase price of approximately $35.4 million, pricing the shares at $4.25 each. Under these agreements, Winning View Investment Limited will acquire 1,436,327 shares, FULL TECH CORPORATE DEVELOPMENT LIMITED will purchase 555,576 shares, and Mapfil Investment Limited will buy 1,111,152 shares, all no later than December 15, 2025. The closings of these transactions are currently expected to be completed in the first half of 2026, though the timeline may be subject to further delays.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDLSsvkS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BYSI","BK4139"],"gpt_icon":0},{"id":"2590061895","title":"BeyondSpring Shares Shares Jump Premarket Following Positive Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2590061895","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590061895?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:38","pubTimestamp":1765543080,"startTime":"0","endTime":"0","summary":"BeyondSpring's shares rallied ahead of the opening bell after the biopharmaceutical company reported positive results among an Asian subset in a late-stage trial of its lung cancer treatment.In Friday's premarket trading, the shares were 16% higher. The stock closed the previous session at $2.18, up 34% in 2025.BeyondSpring said results from a large Asian cohort in its global Phase 3 study evaluating Plinabulin plus docetaxel in second- or third-line epidermal growth factor receptor wild-type non-small cell lung cancer showed a statistically significant improvement in overall survival compared with docetaxel alone.The findings highlight an enhanced benefit in patients whose disease biology aligns with Plinabulin's immune-modulating and tumor vasculature-targeting mechanisms, the company said. It added that the combination also doubled two-year and three-year survival rates.Plinabulin, a brain-penetrating, dendritic-cell maturation small molecule, demonstrated a marked reduction in doce","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"BeyondSpring Shares Shares Jump Premarket Following Positive Trial Results","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BYSI","BK4139"],"gpt_icon":0},{"id":"2590750529","title":"BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path","url":"https://stock-news.laohu8.com/highlight/detail?id=2590750529","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590750529?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:00","pubTimestamp":1765540800,"startTime":"0","endTime":"0","summary":"Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/12/3204554/0/en/BeyondSpring-Announces-ESMO-Asia-Presentation-on-Plinabulin-Docetaxel-Improving-Survival-in-Large-Phase-3-DUBLIN-3-Asian-Subset-for-EGFR-WT-NSCLC-Compared-to-Docetaxel-Strengthenin.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","IE00BHPRN162.USD","BYSI","ITT","WT","BK4161","LU0054578231.USD","LU0053671581.USD","BK4139"],"gpt_icon":0},{"id":"2590518274","title":"BeyondSpring Reports Plinabulin Plus Docetaxel Improves Survival in EGFR Wild-Type NSCLC After Checkpoint Inhibitor Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2590518274","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590518274?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:02","pubTimestamp":1765454522,"startTime":"0","endTime":"0","summary":"BeyondSpring Inc. announced new post-hoc analyses from its global Phase 3 DUBLIN-3 Study, evaluating Plinabulin in combination with docetaxel for patients with EGFR wild-type non-squamous non-small cell lung cancer  who have progressed after anti-PD-1 immunotherapy. The results, presented at the 2025 IASLC/ASCO North America Conference on Lung Cancer , showed that the combination of Plinabulin and docetaxel provided clinically meaningful improvements in overall survival, progression-free survival, and objective response rate compared to docetaxel alone. Specifically, median overall survival was 15.8 months for the combination versus 11.7 months for docetaxel alone, with a hazard ratio of 0.55. Median progression-free survival was 5.6 months versus 3.8 months , and the objective response rate was 18.2% versus 8.0%. The company also reported reductions in brain metastasis and a substantial improvement in metastasis-free survival. BeyondSpring plans to initiate the global Phase 3 DUBLIN-4","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL1qwhfK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BYSI","BK4139","IE00B64PRP62.GBP","LU0314104364.USD","LU2095319765.USD","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014039.USD","BK4588","SG9999014013.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4112","LU2210149790.SGD","IE00BGHQF748.EUR","NDAQ","BK4585","SG9999014021.USD"],"gpt_icon":0},{"id":"2590518191","title":"Beyondspring Announces New Analyses of Dublin-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-Pd-(L)1 for Non-Squamous Egfr Wt Nsclc and a Reduction in Brain Metastasis Compared to Docetaxel at Naclc 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2590518191","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590518191?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:00","pubTimestamp":1765454402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA6JTZ0J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BYSI","BK4139"],"gpt_icon":0},{"id":"2582237554","title":"BeyondSpring Q3 EPS $(0.04) Up From $(0.05) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2582237554","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582237554?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:12","pubTimestamp":1762949545,"startTime":"0","endTime":"0","summary":"BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.04) per share. This is a 20 percent increase over losses of $(0.05) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48799213/beyondspring-q3-eps-0-04-up-from-0-05-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USJW.SI","BYSI","TQQQ","USAW.SI","MNQmain","SQQQ","PSQ","QLD","TSYW.SI",".IXIC","QID","NVIW.SI","BK4139","NQmain"],"gpt_icon":0},{"id":"2582758003","title":"Drugmaker BeyondSpring's Q3 net loss narrows to $1.7 mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2582758003","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582758003?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:08","pubTimestamp":1762949330,"startTime":"0","endTime":"0","summary":"Drugmaker BeyondSpring's Q3 net loss narrows to $1.7 mlnOverviewBeyondSpring Q3 net loss narrows to $1.7 mln from $2.2 mln last yearPlinabulin shows promising results in NSCLC patients at SITC 2025 pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0D2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BYSI","BK4139"],"gpt_icon":0},{"id":"2582730773","title":"BeyondSpring Inc. reports reduced net loss from discontinued operations for nine months ended September 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2582730773","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582730773?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:02","pubTimestamp":1762948963,"startTime":"0","endTime":"0","summary":"BeyondSpring Inc. reported a net loss from discontinued operations of $2.2 million for the nine months ended September 2025, compared to $5.0 million for the same period in 2024. The company reclassified SEED Therapeutics' financial results as discontinued operations after entering definitive agreements in January 2025 to sell the majority of its Series A-1 Preferred Shares in SEED. BeyondSpring currently owns about 38% of SEED, with ownership expected to decrease to approximately 14% following completion of future sale transactions. Key business developments included SEED's completion of a $30 million Series A-3 financing, FDA and China NMPA clearance of its IND application for the lead RBM39 degrader program, and SEED being named a finalist for the 2025 Prix Galien USA \"Best Start-Up\" Award. Additionally, BeyondSpring presented clinical results showing an 85% disease control rate in metastatic NSCLC patients for its dendritic cell maturation agent, Plinabulin, in combination with doc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL63sCxF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BYSI","BK4139"],"gpt_icon":0},{"id":"2582373930","title":"Beyondspring Q3 Net Income USD -1.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373930","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373930?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948804,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLXF10E13:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BYSI"],"gpt_icon":0},{"id":"2582373704","title":"Press Release: BeyondSpring Reports Third--Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373704","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373704?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948800,"startTime":"0","endTime":"0","summary":"-- Two SITC 2025 presentations: First-in-class dendritic cell . maturation agent Plinabulin drives immune re-sensitization in metastatic. NSCLC patients who had progressed after PD-1/L1 inhibitors with disease. control rate of 85% in combination with docetaxel and Keytruda. Mechanism. studies with MD Anderson collaborators showed DC maturation and M1. macrophage polarization via a Plinabulin specific GEF-H1 dependent. mechanism in responding patients with Plinabulin, PD-1 inhibitor and. -- SEED, co-founded by BeyondSpring with 38% equity share, successfully. -- SEED Named Finalist for 2025 Prix Galien USA \"Best Start-Up\" Award. Dr. Huang added, \"At SEED, which we co-founded with Lilly five years ago, we are excited that our RBM39 molecular-glue degrader has received IND clearance from both the US FDA and China NMPA. It is such an honor to be the only target protein degradation company nominated by the Prix Galien Foundation, recognizing our commitment to developing transformative medic","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","ORR","BK4017","BK4555","BK4585","BK4604","BK4097","BK4139","OS","BYSI","DC","TM","BK4211","BK4195","BK4099","PFS","03160"],"gpt_icon":0},{"id":"2577897944","title":"Decheng Capital China Life Sciences USD Fund III, L.P. Reports Sale of BeyondSpring Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2577897944","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577897944?lang=en_us&edition=fundamental","pubTime":"2025-10-21 08:00","pubTimestamp":1761004845,"startTime":"0","endTime":"0","summary":"Decheng Capital China Life Sciences USD Fund III, L.P. reported a disposal of common shares of BeyondSpring Inc. The filing was made by multiple reporting owners, including Decheng Capital China Life Sciences USD Fund III, L.P., Decheng Capital Management III , LLC, Decheng Capital China Life Sciences USD Fund II, L.P., Decheng Capital Management II , LLC, and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 20, 2025, and is sol","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDL6lPBzX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BYSI"],"gpt_icon":0},{"id":"2575763755","title":"Decheng Capital China Life Sciences USD Fund III, L.P. Reports Disposal of Common Shares of BeyondSpring Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2575763755","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575763755?lang=en_us&edition=fundamental","pubTime":"2025-10-16 08:07","pubTimestamp":1760573277,"startTime":"0","endTime":"0","summary":"Decheng Capital China Life Sciences USD Fund III, L.P. reported a disposal of common shares of BeyondSpring Inc. The filing was submitted by multiple reporting owners, including Decheng Capital China Life Sciences USD Fund III, L.P. and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDL4H1PFl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BYSI","BK4139"],"gpt_icon":0},{"id":"2573915339","title":"Decheng Capital China Life Sciences USD Fund III, L.P. Reports Disposal of Common Shares of BeyondSpring Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2573915339","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573915339?lang=en_us&edition=fundamental","pubTime":"2025-10-08 06:15","pubTimestamp":1759875336,"startTime":"0","endTime":"0","summary":"Decheng Capital China Life Sciences USD Fund III, L.P. has reported a disposal of common shares of BeyondSpring Inc. , according to a recent SEC Form 4 filing. The form was filed by more than one reporting person, including Decheng Capital China Life Sciences USD Fund III, L.P. and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 07, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDL2S8CtJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BYSI"],"gpt_icon":0},{"id":"2572522209","title":"Decheng Capital China Life Sciences USD Fund III, L.P. Reports Disposal of Common Shares of BeyondSpring Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2572522209","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572522209?lang=en_us&edition=fundamental","pubTime":"2025-10-03 08:52","pubTimestamp":1759452754,"startTime":"0","endTime":"0","summary":"Decheng Capital China Life Sciences USD Fund III, L.P. has reported a disposal of common shares of BeyondSpring Inc. , according to a recent SEC filing. The form was filed by more than one reporting person, including Decheng Capital China Life Sciences USD Fund III, L.P. and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nNDL3FCLM3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BYSI"],"gpt_icon":0},{"id":"2571436420","title":"Decheng Capital China Life Sciences USD Fund III, L.P. Reports Disposal of Common Shares of BeyondSpring Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2571436420","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571436420?lang=en_us&edition=fundamental","pubTime":"2025-09-30 08:07","pubTimestamp":1759190845,"startTime":"0","endTime":"0","summary":"Decheng Capital China Life Sciences USD Fund III, L.P. has reported the disposal of common shares of BeyondSpring Inc. , according to a recent SEC Form 4 filing. Other reporting beneficial owners were also listed in the filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL201wRZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BYSI","BK4139"],"gpt_icon":0},{"id":"2569710431","title":"Decheng Capital China Life Sciences USD Fund III, L.P. Reports Disposal of Common Shares of BeyondSpring Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2569710431","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569710431?lang=en_us&edition=fundamental","pubTime":"2025-09-24 02:11","pubTimestamp":1758651064,"startTime":"0","endTime":"0","summary":"Decheng Capital China Life Sciences USD Fund III, L.P. has reported a disposal of common shares of BeyondSpring Inc. The form was filed by more than one reporting person, including Decheng Capital China Life Sciences USD Fund III, L.P. and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 19, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDLbv2jtF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BYSI","BK4139"],"gpt_icon":0},{"id":"2566291069","title":"Decheng Capital China Life Sciences USD Fund III, L.P. Reports Disposal of Common Shares of BeyondSpring Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2566291069","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566291069?lang=en_us&edition=fundamental","pubTime":"2025-09-12 07:44","pubTimestamp":1757634265,"startTime":"0","endTime":"0","summary":"Decheng Capital China Life Sciences USD Fund III, L.P. reported a disposal of common shares of BeyondSpring Inc. The form was filed by more than one reporting person, including Decheng Capital China Life Sciences USD Fund III, L.P., among other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 11, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nNDL1hWlfY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BYSI","BK4139"],"gpt_icon":0},{"id":"2566269658","title":"Decheng Capital China Life Sciences USD Fund III, L.P. Reports Disposal of BeyondSpring Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2566269658","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566269658?lang=en_us&edition=fundamental","pubTime":"2025-09-09 06:56","pubTimestamp":1757372174,"startTime":"0","endTime":"0","summary":"Decheng Capital China Life Sciences USD Fund III, L.P. reported a disposal of common shares of BeyondSpring Inc. The form was filed by more than one reporting person, including Decheng Capital China Life Sciences USD Fund III, L.P., among other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL9w6lw9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BYSI","BK4139"],"gpt_icon":0},{"id":"2564483643","title":"Decheng Capital China Life Sciences USD Fund III, L.P. Reports Disposal of Common Shares of BeyondSpring Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2564483643","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564483643?lang=en_us&edition=fundamental","pubTime":"2025-09-04 07:57","pubTimestamp":1756943863,"startTime":"0","endTime":"0","summary":"Decheng Capital China Life Sciences USD Fund III, L.P. reported a disposal of common shares of BeyondSpring Inc. The form was filed by more than one reporting person, including Decheng Capital and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL9ZdvsL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BYSI"],"gpt_icon":0},{"id":"2563937380","title":"Decheng Capital Reports Disposal of Common Shares in BeyondSpring Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2563937380","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563937380?lang=en_us&edition=fundamental","pubTime":"2025-08-29 08:39","pubTimestamp":1756427997,"startTime":"0","endTime":"0","summary":"Decheng Capital China Life Sciences USD Fund III, L.P. reported a disposal of common shares of BeyondSpring Inc. The form was filed by more than one reporting person, including Decheng Capital China Life Sciences USD Fund III, L.P. and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nNDLCG97h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BYSI"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beyondspringpharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.1211},{"period":"3month","weight":-0.1733},{"period":"6month","weight":-0.1302},{"period":"1year","weight":-0.0511},{"period":"ytd","weight":0.0245}],"compareEarnings":[{"period":"1week","weight":-0.0072},{"period":"1month","weight":0.0008},{"period":"3month","weight":0.0203},{"period":"6month","weight":0.0758},{"period":"1year","weight":0.1366},{"period":"ytd","weight":0.0051}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.024767},{"month":2,"riseRate":0.5,"avgChangeRate":-0.048758},{"month":3,"riseRate":0.25,"avgChangeRate":0.104723},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.021214},{"month":5,"riseRate":0.666667,"avgChangeRate":0.086539},{"month":6,"riseRate":0.666667,"avgChangeRate":0.114713},{"month":7,"riseRate":0,"avgChangeRate":-0.133186},{"month":8,"riseRate":0.444444,"avgChangeRate":0.225863},{"month":9,"riseRate":0.555556,"avgChangeRate":-0.062538},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.066821},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.052314},{"month":12,"riseRate":0.444444,"avgChangeRate":0.140673}],"exchange":"NASDAQ","name":"Beyondspring Inc","nameEN":"Beyondspring Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Beyondspring Inc(BYSI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Beyondspring Inc(BYSI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Beyondspring Inc,BYSI,Beyondspring Inc股票,Beyondspring Inc股票老虎,Beyondspring Inc股票老虎国际,Beyondspring Inc行情,Beyondspring Inc股票行情,Beyondspring Inc股价,Beyondspring Inc股市,Beyondspring Inc股票价格,Beyondspring Inc股票交易,Beyondspring Inc股票购买,Beyondspring Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Beyondspring Inc(BYSI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Beyondspring Inc(BYSI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction